| Ident. | Authors (with country if any) | Title |
|---|
| 000004 |
P. Cesaro [France] ; L. Defebvre [France] | Traitement médicamenteux de la maladie de Parkinson à la phase précoce (de novo et « lune de miel ») |
| 000018 |
Serge Pinto [France] ; Murielle Ferraye [France, Pays-Bas] ; Robert Espesser [France] ; Valérie Fraix [France] ; Audrey Maillet [France] ; Jennifer Guirchoum [France] ; Deborah Layani-Zemour [France] ; Alain Ghio [France] ; Stéphan Chabardes [France] ; Pierre Pollak [France, Suisse] ; Bettina Debu [France] | Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility |
| 000028 |
Sylvia Navailles [France] ; Lea Milan [France] ; Hanane Khalki [France] ; Giuseppe Di Giovanni [Royaume-Uni, Malte] ; Mélanie Lagiere [France] ; Philippe De Deurwaerdere [France] | Noradrenergic Terminals Regulate L-DOPA-derived Dopamine Extracellular Levels in a Region-dependent Manner in Parkinsonian Rats |
| 000066 |
C. Gombert [France] ; Y. Nadjar [France] ; D. Grabli [France] | Maladie de Parkinson et réanimation: des problèmes spécifiques ? : URGENCES ET NEUROLOGIE |
| 000085 |
Anna Castrioto [France, Italie] ; Andrea Kistner [France] ; Hélène Klinger [France] ; Eugénie Lhommee [France] ; Emmanuelle Schmitt [France] ; Valérie Fraix [France] ; Stephan Chabardes [France] ; Patrick Mertens [France] ; Jean-Louis Quesada [France] ; Emmanuel Broussolle [France] ; Pierre Pollak [France, Suisse] ; Stéphane C. Thobols [France] ; Paul Krack [France] | Psychostimulant effect of levodopa: reversing sensitisation is possible |
| 000102 |
Hélène Pouclet [France] ; Pascal Derkinderen [France] ; Thibaud Lebouvier [France] | Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease |
| 000106 |
P. Peran [France, Italie] ; F. Nemmi [Italie] ; D. Meligne [France] ; D. Cardebat [France] ; A. Peppe [Italie] ; O. Rascol [France] ; C. Caltagirone [Italie] ; J. F. Demonet [Suisse] ; U. Sabatini [Italie] | Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: A fMRI study |
| 000136 |
E. Roze [France] | Quelles thérapeutiques proposer dans la maladie de Parkinson du sujet âgé ? : Maladie de Parkinson du Sujet Agé |
| 000171 |
P. De Deurwaerdere [France] ; S. Navailles [France] | What can we expect from the serotonergic side of L-DOPA? |
| 000174 |
Laurie Mondillon [France] ; Martial Mermillod [France] ; Serban C. Musca [France] ; Isabelle Rieu [France] ; Tiphaine Vidal [France] ; Patrick Chambres [France] ; Catherine Auxiette [France] ; Helene Dalens [France] ; Louise Marie Coulangeon [France] ; Isabelle Jalenques [France] ; Jean-Jacques Lemaire [France] ; Miguel Ulla [France] ; Philippe Derost [France] ; Ana Marques [France] ; Franck Durif [France] | The combined effect of subthalamic nuclei deep brain stimulation and L-dopa increases emotion recognition in Parkinson's disease |
| 000202 |
Fabrice Billet [France] ; Jean Costentin [France] ; Nathalie Dourmap [France] | Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats |
| 000215 |
Shripad N. Surwase [Inde] ; Sushama A. Patil [Inde] ; Onkar A. Apine [Inde] ; Jyoti P. Jadhav [Inde] | Efficient Microbial Conversion of L-Tyrosine to L-DOPA by Brevundimonas sp. SGJ |
| 000224 |
Santiago Perez-Lloret [France] ; Maria Veronica Rey [France] ; Nelly Fabre [France] ; Fabienne Ory [France] ; Umberto Spampinato [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Do Parkinson's disease patients disclose their adverse events spontaneously? |
| 000235 |
P.-O. Fernagut [France] ; F. Tison [France] | ANIMAL MODELS OF MULTIPLE SYSTEM ATROPHY |
| 000236 |
H. Iderberg [Suède] ; V. Francardo [Suède] ; E. Y. Pioll [Royaume-Uni] | ANIMAL MODELS OF L-DOPA-INDUCED DYSKINESIA: AN UPDATE ON THE CURRENT OPTIONS |
| 000244 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
| 000252 |
J. P. Azulay [France] | Évaluation d'un effet disease modifier dans la maladie de Parkinson : quel schéma d'étude? : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000260 |
I. Benatru [France] ; C. Fayard [France] | Place de la L-dopa dans la maladie de Parkinson en 2011 |
| 000266 |
P. Cesaro [France] | Maladie de Parkinson : les enjeux du traitement : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000267 |
Sophie Bayard [France] ; Valérie Cochen De Cock [France] ; Yves Dauvillers [France] | Le syndrome de dysrégulation dopaminergique dans la maladie de Parkinson et le syndrome des jambes sans repos |
| 000295 |
Timothy P. Gilmour [États-Unis] ; Christopher A. Lieu [États-Unis] ; Mark J. Nolt [États-Unis] ; Brigitte Piallat [France] ; Milind Deogaonkar [États-Unis] ; Thyagarajan Subramanian [États-Unis] | The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys |
| 000299 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease |
| 000311 |
Elaine Del-Bel [France] ; Fernando Eduardo Padovan-Neto [France] ; Rita Raisman-Vozarl [France] ; Marcio Lazzarini [France] | Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment |
| 000315 |
E. D'Aurizio [Italie] ; C. F. Van Nostrum [Pays-Bas] ; M. J. Van Steenbergen [Pays-Bas] ; P. Sozio [Italie] ; F. Siepmann [France] ; J. Siepmann [France] ; W. E. Hennink [Pays-Bas] ; A. Di Stefano [Italie] | Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug |
| 000326 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
| 000339 |
Imtiaz Ahmed [Royaume-Uni] ; Subrata K. Bose [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Anil Ramlackhansingh [Royaume-Uni] ; Federico Turkheimer [Royaume-Uni] ; Gary Hotton [Royaume-Uni] ; Alexander Hammers [Royaume-Uni, France] ; David J. Brooks [Royaume-Uni] | Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias |
| 000360 |
M. Carta [Suède, Italie] ; E. Bezard [France] | CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA |
| 000367 |
Brigitte Spinnewyn [France] ; Christelle Charnet [France] ; Sylvie Cornet [France] ; Veronique Roubert [France] ; Pierre-Etienne Chabrier [France] ; Michel Auguet [France] | An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats |
| 000479 |
Daniella Rylander [Suède] ; Martin Parent [Canada] ; Sean S. O'Sullivan [Royaume-Uni] ; Sandra Dovero [France] ; Andrew J. Lees [Royaume-Uni] ; Erwan Bezard [France] ; Laurent Descarries [Canada] ; M. Angela Cenci [Suède] | Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced Dyskinesia |
| 000486 |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [États-Unis] | Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study |
| 000543 |
Maeva Jego ; Francois Viallet [France] | Maladie de Parkinson du sujet âgé. Prise en charge thérapeutique : médicaments à prescrire et médicaments à éviter |
| 000578 |
Olivier Berton [États-Unis] ; Céline Guigoni [France] ; QIN LI [France] ; Bernard H. Bioulac [France] ; Incarnation Aubert [France] ; Christian E. Gross [France] ; Ralph J. Dileone [États-Unis] ; Eric J. Nestler [États-Unis] ; Erwan Bezard [France, République populaire de Chine] | Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease |
| 000585 |
Clemence Simonin [France] ; M. Tir [France] ; D. Devos [France] ; A. Kreisler [France] ; K. Dujardin [France] ; J. Salleron [France] ; A. Delval [France] ; S. Blond [France] ; L. Defebvre [France] ; A. Destee [France] ; P. Krystkowiak [France] | Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon |
| 000596 |
David Devos [France] | Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson's Disease |
| 000625 |
A. Degardin [France] ; E. Houdayer [France] ; J.-L. Bourriez [France] ; A. Destee [France] ; L. Defebvre [France] ; P. Derambure [France] ; D. Devos [France] | Deficient "sensory" beta synchronization in Parkinson's disease |
| 000640 |
Caroline Moreau [France] ; Alain Destée [France] ; T. Foltynie [Royaume-Uni] ; B. Cheeran [Royaume-Uni] ; C. H. Williams-Gray [Royaume-Uni] ; M. J. Edwards [Royaume-Uni] ; S. A. Schneider [Royaume-Uni] ; D. Weinberger [États-Unis] ; J. C. Rothwell [Royaume-Uni] ; R. A. Barker [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] | BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. Commentary |
| 000644 |
Joëlle Micallef [France] ; Marc Rey [France] ; Alexandre Eusebio [France] ; Christine Audebert [France] ; Frank Rouby [France] ; Elisabeth Jouve [France] ; Sophie Tardieu [France] ; Oliver Blin [France] | Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects |
| 000667 |
O. Rascol [France] | Thérapeutiques du stade précoce de la maladie de Parkinson |
| 000692 |
Erwan Bezard [France] | L-dopa, un jour et pour toujours |
| 000718 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
| 000726 |
Anne Beuter [France] ; Roberto Hernandez [Canada] ; Robert Rigal [Canada] ; Julien Modolo [France] ; Pierre J. Blanchet [Canada] | Postural Sway and Effect of Levodopa in Early Parkinson's Disease |
| 000763 |
M. U. Ferraye [France] ; B. Debu [France] ; V. Fraix [France] ; J. Xie-Brustolin [France] ; S. Chabardes [France] ; P. Krack [France] ; A.-L. Benabid [France] ; P. Pollak [France] | Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease |
| 000778 |
Ana Munoz [Suède] ; QIN LI [République populaire de Chine] ; Fabrizio Gardoni [Italie] ; Elena Marcello [Italie] ; CHUAN QIN [République populaire de Chine] ; Thomas Carlsson [Suède] ; Deniz Kirik [Suède] ; Monica Di Luca [Italie] ; Anders Björklund [Suède] ; Erwan Bezard [France] ; Manolo Carta [Suède] | Combined 5-HTjA and 5-HTjB receptor agonists for the treatment of L-DOPA-induced dyskinesia |
| 000828 |
T. Slaoui [France] ; A. Mas-Gerdelat [France] ; F. Ory-Magne [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien |
| 000844 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
| 000860 |
Vincent Paille [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
| 000865 |
B. Ballanger [France] ; R. Gil [France] ; M. Audiffren [France] ; M. Desmurget [France] | Perceptual factors contribute to akinesia in Parkinson's disease |
| 000882 |
A. Gerdelat-Mas [France] ; M. Simonetta-Moreau [France] ; C. Thalamas [France] ; F. Ory-Magne [France] ; T. Slaoui [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | Levodopa raises objective pain threshold in Parkinson's disease : a Rill reflex study |
| 000917 |
Pauline Delaveau [France] ; Pilar Salgado-Pineda [France] ; Joëlle Micallef-Roll [France] ; Olivier Blin [France] | Amygdala activation modulated by levodopa during emotional recognition processing in healthy volunteers : A double-blind, placebo-controlled study |
| 000937 |
Jean-Louis Montastruc [France] ; Agnès Sommet [France] ; Pascale Olivier [France] ; Haieh Bagheri [France] ; Mireille Gony [France] ; Maryse Lapeyre-Mestre [France] ; Christine Brefel-Courbon [France] ; Joachim Ferreira [Portugal] ; Laurent Schmitt [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] | Médicaments, maladie de Parkinson et syndromes parkinsoniens : actualités de pharmacovigilance |
| 000943 |
Philippe Damier [France] ; Pascal Derkinderen [France] | Les particularités du traitement de la maladie de Parkinson chez le sujet âgé |
| 000946 |
Marc Ziegler [France] | La maladie de Parkinson évoluée |
| 000968 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease |
| 000974 |
Jean-Pierre Wolf [France] ; Malika Bouhaddi [France] ; Francis Louisy [France] ; Andrei Mikehiev [France] ; Laurent Mourot [France] ; Sylvie Cappelle [France] ; Fabrice Vuillier [France] ; Pierre Andre [France] ; Lucien Rumbach [France] ; Jacques Regnard [France] | Side-effects of l-dopa on venous tone in Parkinson's disease : a leg-weighing assessment |
| 000983 |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lledo [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study |
| 000A05 |
D. Guehl [France] ; P. Dehail [France] ; M. P. De Seze [France] ; E. Cuny [France] ; P. Faux [France] ; F. Tison [France] ; M. Barat [France] ; B. Bioulac [France] ; P. Burbaud [France] | Evolution of postural stability after subthalamic nucleus stimulation in Parkinson's disease : a combined clinical and posturometric study |
| 000A08 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardes [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
| 000A10 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease : A planned seven-month report of the REGAIN study |
| 000A13 |
Karsten Witt [Allemagne] ; Christine Daniels [Allemagne] ; Jan Herzog [Allemagne] ; Delia Lorenz [Allemagne] ; Jens Volkmann [Allemagne] ; Julia Reiff [Allemagne] ; Maximilian Mehdorn [Allemagne] ; Gunther Deuschl [Allemagne] ; Paul Krack [France] | Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease |
| 000A14 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa |
| 000A33 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors |
| 000A35 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000A82 |
S. Thobois [France] ; E. Broussolle [France] ; P. Remy [France] | Contribution et limites de l'imagerie fonctionnelle dans l'évaluation des traitements à visée neuroprotectrice dans la maladie de Parkinson |
| 000A86 |
Stéphane Thobois [France] ; Florence Delamarre-Damier [France] ; Pascal Derkinderen [France] | Treatment of motor dysfunction in Parkinson's disease: an overview |
| 000A91 |
D. Centonze [Italie] ; P. Gubellini [France] ; S. Rossi [Italie] ; B. Picconi [Italie] ; A. Pisani [Italie] ; G. Bernardi [Italie] ; P. Calabresi [Italie] ; C. Baunez [France] | Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism |
| 000A97 |
Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne] | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary |
| 000B09 |
Jean-Pascal Lefaucheur [France] | Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation |
| 000B13 |
Incarnation Aubert [France] ; Céline Guigoni [France] ; Kerstin Hakansson [Suède] ; QIN LI [République populaire de Chine] ; Sandra Dovero [France] ; Nicole Barthe [France] ; Bernard H. Bioulac [France] ; Christian E. Gross [France] ; Gilberto Fisone [Suède] ; Bertrand Bloch [France] ; Erwan Bezard [France] | Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia |
| 000B26 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
| 000B30 |
Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; Francois Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France] | Effect of levodopa on pain threshold in Parkinson's disease : A clinical and positron emission tomography study |
| 000B42 |
Véronique Sgambato-Faure [France] ; Virginie Buggia [France] ; Frangois Gilbert [Canada] ; Daniel Levesque [Canada] ; Alim-Louis Benabid [France] ; Francois Berger [France] | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-lnduced behavioral sensitization in dyskinetic rats |
| 000B49 |
Serge Pinto [France] ; Michèle Gentil [France] ; Paul Krack [France] ; Paul Sauleau [France] ; Valérie Fraix [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech |
| 000B50 |
Carine Chassain [France] ; Guy Bielicki [France] ; Jean-Pierre Donnat [France] ; Jean-Pierre Renou [France] ; Alain Eschalier [France] ; Franck Durif [France] | Cerebral glutamate metabolism in Parkinson's disease : an in vivo dynamic 13C NMS study in the rat |
| 000B74 |
J.-M. Soler [France] ; B. Le Portz [France] | Les troubles vésicosphinctériens de la maladie de Parkinson |
| 000B77 |
Luc Defebvre [France] | Les complications motrices de la dopathérapie chez le malade parkinsonien: sémiologie clinique et modalités d'évaluation |
| 000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000C13 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study |
| 000C14 |
Paula Ravenscroft [Royaume-Uni] ; Sylvie Chalon [France] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] | Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia |
| 000C15 |
Vincent Paille [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease |
| 000C32 |
Jill L. Smith [France] ; Jeong-Sun Ju [France] ; Bithika M. Saha [France] ; Brad A. Racette [France, États-Unis] ; Jonathan S. Fisher [France] | Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle |
| 000C33 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio ; Fabrizio Stocchi | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 000C34 |
Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
| 000C40 |
M. Bouhaddi [France] ; F. Vuillier [France] ; J. O. Forkat [France] ; S. Cappelle [France] ; M. T. Henriet [France] ; L. Rumbach [France] ; J. Regnard [France] | Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy |
| 000C53 |
Juan E. Ferrario [Argentine] ; Irene R. E. Taravini [Argentine] ; Sophie Mourlevat [France] ; Andrea Stefano [Argentine] ; Marina A. Delfino [Argentine] ; Rita Raisman-Vozari [France] ; M. Gustavo Murer [Argentine] ; Merle Ruberg [France] ; Oscar Gershanik [Argentine] | Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system |
| 000C85 |
F. Ghawche [France] ; F. Durif [France] | Traitement dopaminergique et syndromes parkinsoniens |
| 000C99 |
E. Polard [France] ; E. Trioux [France] ; L. Flet [France] ; F. Colin [France] ; H. Allain [France] | Ludopathie induite par la lévodopa associée à la bromocriptine |
| 000D16 |
A. Funkiewiez [France] ; C. Ardouin [France] ; P. Krack [France] ; V. Fraix ; N. Van Blercom [France] ; J. Xie [France] ; E. Moro [France] ; A.-L. Benabid [France] ; P. Pollak [France] | Effets psychotropes aigus de la stimulation subthalamique bilatérale et de la lévodopa dans la maladie de Parkinson |
| 000D22 |
J.-L. Montastruc [France] ; L. Schmitt [France] ; H. Bagheri [France] | Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine |
| 000D41 |
R. Bordet [France] ; D. Devos [France] ; S. Brique [France] ; Y. Touitou [France] ; J. D. Guieu [France] ; C. Libersa [France] ; A. Destee [France] | Study of circadian melatonin secretion pattern at different stages of Parkinson's disease |
| 000D42 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000D51 |
Christian E. Gross [France] ; Paula Ravenscroft [France] ; Sandra Dovero [France] ; Mohamed Jaber [France] ; Bernard Bioulac [France] ; Erwan Bezard [France] | Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice |
| 000D54 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 000D70 |
Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France] | Limitations of current Parkinson's disease therapy. Discussion |
| 000D71 |
Mauro Maccarrone [Italie] ; Paolo Gubellini [France, Italie] ; Monica Bari [Italie] ; Barbara Picconi [Italie] ; Natalia Battista [Italie] ; Diego Centonze [Italie] ; Giorgio Bernardi [Italie] ; Alessandro Finazzi-Agro [Italie] ; Paolo Calabresi [Italie] | Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism |
| 000D80 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 000D81 |
G. Fenelon [France] ; S. Gimenez-Roldan [Espagne] ; J. L. Montastruc [France] ; F. Bermejo [Espagne] ; F. Durif [France] ; I. Bourdeix [France] ; J.-J. Pere [Espagne] ; L. Galiano [Suisse] ; J. Schadrack | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study |
| 000D83 |
Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Jean-Louis Bourriez [France] ; Alain Duhamel [France] ; Miriam Perina [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France] ; Luc Defebvre [France] | Effects of subthalamic nucleus stimulation and levodopa treatment on gait abnormalities in Parkinson disease |
| 000D84 |
Charles Crevoisier [Suisse] ; Patricia Zerr [France] ; Francoise Calvi-Gries [France] ; Turid Nilsen [Norvège] | Effects of food on the pharmacokinetics of levodopa in a dual-release formulation |
| 000D85 |
Céline Perier [France] ; Concepcio Marin [Espagne] ; Anna Jimenez [Espagne] ; Mercè Bonastre [Espagne] ; Eduardo Tolosa [Espagne] ; Etienne C. Hirsch [France] | Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats |
| 000D88 |
D. Devos [France] ; E. Labyt [France] ; P. Derambure [France] ; J. L. Bourriez [France] ; F. Cassim [France] ; J. D. Guieu [France] ; A. Destee [France] ; L. Defebvre [France] | Effect of L-dopa on the pattern of movement-related (de)synchronisation in advanced Parkinson's disease |
| 000D91 |
H. Mollion [France] ; J. Ventre-Dominey [France] ; P. F. Dominey [France] ; E. Broussolle [France] | Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease |
| 000D95 |
C. Crevoisier [Suisse] ; A. Monreal [France] ; B. Metzger [France] ; T. Nilsen [Norvège] | Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers |
| 000E11 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; JING XIE [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease |
| 000E23 |
J.-L. Houeto [France] ; I. Arnulf [France] | Troubles psychiques et somnolence |
| 000E28 |
A. Destee [France] ; R. Bordet [France] | Stimulation dopaminergique continue, stimulation dopaminergique pulsatile |
| 000E33 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
| 000E36 |
F. Viallet [France] ; T. Witjas [France] | Neuroplasticité et maladie de Parkinson |
| 000E42 |
| Maladie de Parkinson |
| 000E46 |
A. Nieoullon [France] ; M. Amalric [France] | Les récepteurs dopaminergiques : aspects structuraux et implications fonctionnelles |
| 000E47 |
Ph. Damier [France] | Les fluctuations |
| 000E63 |
F. Durif [France] | Fluctuations motrices |
| 000E64 |
P. Derkinderen [France] ; M. Vidailhet [France] | Dyskinésies provoquées par la L-DOPA |
| 000E91 |
Elena Moro [France, Italie] ; Rianne J. A. Esselink [France, Pays-Bas] ; Alim Louis Benabid [France] ; Pierre Pollak [France] | Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation |
| 000E92 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 000F16 |
V. Czernecki [France] ; B. Pillon [France] ; J. L. Houeto [France] ; J. B. Pochon [France] ; R. Levy [France] ; B. Dubois [France] | Motivation, reward, and Parkinson's disease: influence of dopatherapy |
| 000F26 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 000F35 |
Luc J. P. Defebvre [France] ; Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Alain Duhamel [France] ; Jean-Louis Bourriez [France] ; Myriame Perina [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France] | Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease |
| 000F56 |
Yoshimi Misu [Japon] ; Nobuya Furukawa [Japon] ; Nobutaka Arai [Japon] ; Takeaki Miyamae [Japon] ; Yoshio Goshima [Japon] ; Kiyohide Fujita [Japon] | DOPA causes glutamate release and delayed neuron death by brain ischemia in rats |
| 000F63 |
C. Lebrun-Frenay [France] ; M. Borg [France] | Choosing the right dopamine agonist for patients with Parkinson's disease |
| 000F66 |
Bernard Bruguerolle [France] ; Nicolas Simon [France] | Biologic rhythms and Parkinson's disease: A chronopharmacologic approach to considering fluctuations in function |
| 000F90 |
| Intérêt thérapeutique du pergolide par rapport à la bromocriptine chez les parkinsoniens traités par L-dopa : revue des principaux essais cliniques publiés |
| 000F97 |
A. N. Lieberman ; A. Neophytides ; M. Leibowitz | Substitution entre pergolide et bromocriptine chez les parkinsoniens sous L-dopa |
| 001015 |
G. Kemoun [France] ; L. Defebvre [France] | Enrayages cinétiques et chutes : prise en charge thérapeutique : Troubles de la marche dans la maladie de Parkinson |
| 001019 |
G. Kemoun [France] ; L. Defebvre [France] | Description clinique analyse de la posture, de l'initiation et de la marche stabilisée : Troubles de la marche dans la maladie de Parkinson |
| 001020 |
| Comparaison directe de l'efficacité et de la tolérance du pergolide et de la bromocriptine en association à la L-dopa chez les parkinsoniens fluctuants |
| 001021 |
Yves Agid [France] ; H. Dechy ; A. Destee ; P. Hinault ; E. Broussolle ; T. H. Dechy | Attitude pratique face aux complications de la L-dopathérapie chez les patients parkinsoniens fluctuants |
| 001026 |
Jaime Sanabria [Espagne] ; Pedro Garcia Ruiz [Espagne] ; Raimundo Gutierrez [Espagne] ; Francisco Marquez [Espagne] ; Paloma Escobar [Espagne] ; Michele Gentil [France] ; Carlos Cenjor [Espagne] | The effect of levodopa on vocal function in Parkinson's disease |
| 001048 |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
| 001050 |
Yves Agid [France] | Levodopa: Is toxicity a myth? |
| 001070 |
F. Durif [France] ; I. Devaux [France] ; J.-J. Pere [France] ; J.-C. Delumeau [Suisse] ; I. Bourdeix [France] | Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's Disease and end-of-dose deterioration in daily medical practice : An open, multicenter study |
| 001071 |
Bertrand Herer [France] ; Isabelle Arnulf [France] ; Bruno Housset [France] | Effects of levodopa on Pulmonary function in Parkinson's disease |
| 001072 |
V. Fraix [France] ; P. Pollak ; N. Van Blercom ; J. Xie ; P. Krack [Allemagne] ; A. Koudsie ; A. L. Benabid | Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease |
| 001073 |
JING XIE [France] ; Paul Krack [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Effect of bilateral subthalamic nucleus stimulation on parkinsonian gait |
| 001077 |
Olivier Rascol [France] ; Nelly Fabre [France] | Dyskinesia: L-dopa-induced and tardive dyskinesia |
| 001078 |
S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France] | Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease |
| 001080 |
Thomas Boraud [France] ; Erwan Bezard [France] ; Bernard Bioulac [France] ; Christian E. Gross [France] | Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey |
| 001085 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 001086 |
Pierre Krystkowiak [France] ; Jean Louis Blatt [France] ; Jean Louis Bourriez [France] ; Alain Duhamel [France] ; Myriam Perina [France] ; Gilles Kemoun [France] ; Serge Blond [France] ; Jean Daniel Guieu [France] ; Alain Destée [France] ; Luc Defebvre [France] | Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease : a study using a video motion analysis system |
| 001109 |
Yves Agid [France] | Une façon d'examiner un patient parkinsonien |
| 001114 |
P. Derkinderen [France] | Stratégies thérapeutiques conseillées à la phase initiale de la maladie |
| 001125 |
E. Broussolle [France] | Place de la Dopa-thérapie dans le traitement initial de la maladie de Parkinson |
| 001140 |
Pierre Sokoloff [France] | Le père de la dopamine |
| 001155 |
P. Damier [France] ; L. Tramblay [France] ; J. Feger [France] ; E. C. Hirsch [France] | Développement des dyskinésies provoquées par le traitement de la maladie de Parkinson : rôle de la première exposition à la L-DOPA (ou phénomène du « priming ») |
| 001176 |
O. Rascol [France] | The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease |
| 001189 |
E. C. Hirsch [France] ; BENABID ; OLANOW ; SEALFON ; HALLETT ; LANGSTON ; CALABRESI | Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. Discussion |
| 001196 |
O. Rascol [France] | Medical treatment of levodopa-induced dyskinesias |
| 001200 |
B.-P. Bejjani [France, Liban] ; I. Arnulf [France] ; S. Demeret [France] ; P. Damier [France] ; A.-M. Bonnet [France] ; J.-L. Houeto [France] ; Yves Agid [France] | Levodopa-induced dyskinesias in Parkinson's disease : Is sensitization reversible? |
| 001205 |
A.-M. Bonnet [France] | Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications |
| 001216 |
H. Allain [France] ; A. Destee [France] ; H. Petit [France] ; M. Patay [France] ; S. Schück [France] ; D. Bentue-Ferrer [France] ; P. Le Cavorzin [France] | Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease |
| 001221 |
T. Boraud [France] ; E. Bezard [France] ; J. M. Stutzmann [France] ; B. Bioulac [France] ; C. E. Gross [France] | Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey |
| 001222 |
V. Fraix [France] ; P. Pollak ; N. Van Blercom ; J. Xie ; P. Krack [Allemagne] ; A. Koudsie ; A. L. Benabid | Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease |
| 001225 |
A. L. Benabid [France] ; A. Benazzouz [France] ; P. Limousin [France] ; A. Koudsie [France] ; P. Krack [Allemagne] ; B. Piallat [France] ; P. Pollak [France] | Dyskinesias and the subthalamic nucleus |
| 001231 |
C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] | Continuous dopamine-receptor stimulation in early Parkinson's disease |
| 001234 |
M.-J. Ribeiro [France, Portugal] ; P. Remy [France] ; B. Bendriem [États-Unis, France] ; P. Almeida [France, Portugal] ; V. Brulon [France] ; Y. Samson [France] ; B. Maziere [France] ; R. Trebossen [France] | Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa |
| 001239 |
B.-P. Bejjani [France, Liban] ; D. Gervais [France] ; I. Arnulf [France] ; S. Papadopoulos [France] ; S. Demeret [France] ; A.-M. Bonnet [France] ; P. Cornu [France] ; P. Damier [France] ; Yves Agid [France] | Axial parkinsonian symptoms can be improved : The role of levodopa and bilateral subthalamic stimulation |
| 001262 |
L. Defebvre [France] ; MARCHANDISE ; VIDAILHET ; TOUCHON ; CHACCOUR ; TRANQUART ; SAMSON ; MELKI | Traitement médical de la maladie de Parkinson. Discussion |
| 001273 |
P. Remy [France] ; P. Hantraye [France] ; Y. Samson [France] | La tomographie par émission de positions, un outil de recherche fondamentale devenu indispensable à la recherche clinique : L'exemple des greffes neuronales dans la maladie de Parkinson |
| 001278 |
D. Caparros-Lefebvre ; P. Pollak [France] ; M. P. Feltin [France] ; S. Blond [France] ; A. L. Benabid [France] | Effet de la stimulation thalamique sur les dyskinésies induites par la L-dopa : évaluation d'une cible nouvelle : Le centre médian parafasciculaire |
| 001282 |
G. L. Defer [France] | Controverse sur le traitement initial de la maladie de parkinson : L-dopa ou agonistes dopaminergiques ? |
| 001284 |
E. Broussolle [France] | Arguments en faveur du traitement initial de la maladie de Parkinson par la L-dopa |
| 001285 |
J. C. Homberg [France] | Anémies hémolytiques autoimmunes dues à des médicaments |
| 001297 |
M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France] | The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease |
| 001325 |
M.-P. Muriel [France] ; V. Bernard [France] ; A. I. Levey [États-Unis] ; O. Laribi [France] ; D. N. Abrous [France] ; Yves Agid [France] ; B. Bloch [France] ; E. C. Hirsch [France] | Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease |
| 001326 |
M. G. Murer [Argentine] ; R. Raisman-Vozari [France] ; O. Gershanik [Argentine] | Levodopa in Parkinson's disease : Neurotoxicity issue laid to rest? |
| 001330 |
O. Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
| 001332 |
M. G. Murer [Argentine] ; J. Ferrario [Argentine] ; M. Delfino [Argentine] ; G. Dziewczapolski [Argentine] ; O. S. Gershanik [Argentine] ; R. Raisman-Vozari [France] | Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions |
| 001333 |
D. Caparros-Lefebvre [France] ; S. Blond [France] ; M.-P. Feltin [France] ; P. Pollak [France] ; A. L. Benabid [France] | Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement : possible involvement of the centre median and parafascicularis complex |
| 001339 |
P. Krack [France, Allemagne] ; P. Pollak [France] ; P. Limousin [France, Royaume-Uni] ; A. Benazzouz [France] ; G. Deuschl [Allemagne] ; A.-L. Benabid [France] | From off-period dystonia to peak-dose chorea : The clinical spectrum of varying subthalamic nucleus activity |
| 001342 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 001345 |
E. Bezard [France] ; C. Brefel [France] ; F. Tison [France] ; H. Peyro-Saint-Paul [France] ; P. Ladure [France] ; O. Rascol [France] ; C. E. Gross [France] | Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in mptp-treated monkey |
| 001347 |
M. Gentil [France] ; C.-L. Tournier [France] ; P. Pollak [France] ; A. L. Benabid [France] | Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease |
| 001357 |
L. Vercueil [France] ; J. P. Linard [France] ; B. Wuyam [France] ; P. Pollak [France] ; G. Benchetrit [France] | Breathing pattern in patients with Parkinson's disease |
| 001371 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
| 001386 |
O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France] | Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens |
| 001407 |
C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France] | α2-Adrenoceptor antagonists: A new approach to Parkinson's disease? |
| 001422 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001429 |
P. Krack [France] ; P. Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; J. F. Le Bas [France] ; A. Koudsie [France] ; A. L. Benabid [France] | Opposite motor effects of pallidal stimulation in Parkinson's disease |
| 001439 |
Yves Agid [France] | Levodopa : Is toxicity a myth? |
| 001442 |
P. Krack [France] ; P. Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; A.-L. Benabid [France] | Inhibition of levodopa effects by internal pallidal stimulation |
| 001443 |
L. Defebvre [France] ; J. L. Bourriez [France] ; P. Derambure [France] ; A. Duhamel [France] ; J. D. Guieu [France] ; A. Destee [France] | Influence of chronic administration of L-DOPA on event-related desynchronization of mu rhythm preceding voluntary movement in Parkinson's disease |
| 001451 |
M. Gentil [France] ; C.-L. Tournier [France] ; S. Perrin [France] ; P. Pollak [France] | Effects of levodopa on finger and orofacial movements in Parkinson's disease |
| 001461 |
O. Rascol [France] ; U. Sabatini [France, Italie] ; C. Brefel [France] ; N. Fabre [France] ; S. Rai [France] ; J. M. Senard [France] ; P. Celsis [France] ; G. Viallard [France] ; J. L. Montastruc [France] ; F. Chollet [France] | Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia |
| 001463 |
M. G. Murer [France] ; G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. C. Garcia [Argentine] ; Yves Agid [France] ; O. Gershanik [Argentine] ; R. Raisman-Vozari [France] | Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions |
| 001502 |
P. Pollak [France] | Mécanismes et traitements de la maladie de Parkinson : Mouvements anormaux |
| 001506 |
G. Fenelon [France] | Maladie de Parkinson : Le traitement médical : Maladie de Parkinson |
| 001523 |
O. Rascol [France] ; N. Fabre [France] ; J.-L. Montastruc [France] | Fluctuations de la réponse à la L-dopa dans la maladie de Parkinson : Maladie de Parkinson - 2e partie |
| 001529 |
M. Vidailhet [France] | Dyskinésies provoquées par la L-dopa : Maladie de Parkinson - 2e partie |
| 001530 |
A. Destee [France] | Données séméiologiques et principes actuels du traitement médical |
| 001543 |
Yves Agid [France] ; A. Destee ; F. Durif ; J.-L. Montastruc ; P. Pollak | Tolcapone, bromocriptine, and Parkinson's disease |
| 001559 |
B. Bejjani [France] ; P. Damier [France] ; I. Arnulf [France] ; A. M. Bonnet [France] ; M. Vidailhet [France] ; D. Dormont [France] ; B. Pidoux [France] ; P. Cornu [France] ; C. Marsault [France] ; Yves Agid [France] | Pallidal stimulation for Parkinson's disease : Two targets? |
| 001587 |
P. Krack [Allemagne] ; P. Limousin [France] ; A. L. Benabid [France] ; P. Pollak [France] | Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease |
| 001590 |
U. K. Rinne [Finlande] ; F. Bracco [Italie] ; C. Chouza [Uruguay] ; E. Dupont [Danemark] ; O. Gershanik [Argentine] ; J. F. Marti Masso [Espagne] ; J. L. Montastruc [France] ; C. D. Marsden [Royaume-Uni] ; A. Dubini [Italie] ; N. Orlando [Italie] ; R. Grimaldi [Italie] | Cabergoline in the treatment of early Parkinson's disease : Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa |
| 001626 |
J. P. Azulay [France] ; C. Van Den Brand ; D. Mestre [France] ; O. Blin [France] ; I. Sangla [France] ; J. Pouget [France] ; G. Serratrice [France] | Analyse cinématique de la marche du parkinsonien : Effets de la levodopa et de stimulations visuelles |
| 001649 |
A. F. Carpentier [France] ; A. M. Bonnet [France] ; M. Vidailhet [France] ; Yves Agid [France] | Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease |
| 001654 |
M. T. Herrero [Espagne] ; S. J. Augood [Royaume-Uni] ; H. Asensi [Espagne] ; E. C. Hirsch [France] ; Yves Agid [France] ; J. A. Obeso [Espagne] ; P. C. Emson [Royaume-Uni] | Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys |
| 001672 |
M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients |
| 001723 |
F. Durif [France] ; M. Vidailhet ; A. M. Bonnet ; J. Blin ; Yves Agid [France] | Levodopa-induced dyskinesias are improved by fluoxetine |
| 001745 |
A. M. Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
| 001764 |
L. Rumbach [France] | Maladie de Parkinson: la L-dopa reste le traitement de base |
| 001771 |
M. Ziegler [France] | Etude multicentrique de Sinemet® LP 200(carbidopa-lévodopa 50/200) à la libération prolongée dans le traitement de la maladie de Parkinson chez des patients avec et sans fluctuations d'efficacité |
| 001791 |
O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; P. Calsis [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France] | Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa |
| 001797 |
R. Marconi [France] ; D. Lefebvre-Caparros ; A.-M. Bonnet [France] ; M. Vidailhet [France] ; B. Dubois [France] ; Yves Agid [France] | Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology |
| 001806 |
M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi ; N. Gouider-Khouja ; Y. Agig [France] | Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot ? |
| 001808 |
A. Kastner [France] ; M. T. Herrero [France] ; E. C. Hirsch [France] ; J. Guillen ; M. R. Luquin ; F. Javoy-Agid [France] ; J. A. Obeso ; Yves Agid [France] | Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay |
| 001816 |
J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] ; A. Rascol | A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up |
| 001910 |
F. Dubas [France] ; M. Vidailhet [France] ; D. Henin [France] | Syndrome parkinsonien peu réactif à la dopa thérapie chez un homme de 64 ans |
| 001A24 |
O. Blin ; A. M. Ferrandez ; J. Pailhous ; G. Serratrice | Une nouvelle méthode d'analyse quantitative de la marche du Parkinsonien : illustration sur 6 patients |
| 001A25 |
O. Blin ; A. M. Ferrandez ; J. Pailhous ; G. Serratrice | Une nouvelle méthode d'analyse quantitative de la marche du Parkinsonien : illustration sur 6 patients |
| 001A32 |
F. Jacquemard [France] ; J. C. Palaric ; H. Allain ; J. R. Giraud | Maladie de Parkinson et grossesse : a propos d'un cas |
| 001A43 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Comparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée |
| 001A48 |
G. Durrieu [France] ; Y. Rispail ; E. Chatelut ; M. Berlan ; A. Rascol ; J.-L. Montastruc ; P. Montastruc | β-Adrenergic sensitivity in Parkinson's disease : effect of levodopa treatment |
| 001B00 |
B. Pillon ; B. Dubois ; A.-M. Bonnet ; M. Esteguy ; J. Guimaraes ; J.-M. Vigouret ; F. Lhermitte ; Yves Agid [France] | Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test |
| 001B01 |
O. Rascol ; M. Clanet ; J. L. Montastruc ; M. Simonetta ; M. J. Soulier-Esteve ; B. Doyon ; A. Rascol | Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems |
| 001B15 |
M. Ziegler | L'évolution du parkinsonien traité |
| 001B17 |
J.-P. Marc-Vergnes ; P. Celsis ; J. L. Montastruc ; J. F. Demonet ; A. Agniel ; O. Rascol ; G. Viallard ; B. Doyon ; A. Rascol | Hémodynamique cérébrale et pharmacologie clinique dans la maladie de Parkinson |
| 001B20 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Bromocriptine versus levodopa dans le traitement de première intention de la maladie de Parkinson. Premiers résultats à deux ans |
| 001B47 |
A. Devaux | Dyskinésies tardives: rôle de la pyridoxine dans la prévention |
| 001B51 |
M. Ziegler ; V. Fournier ; N. Bathien ; P. L. Morselli ; P. Rondot | Therapeutic response to progabide in neuroleptic- and L-DOPA-induced dyskinesias |
| 001B58 |
J. L. Montastruc ; P. Celsis ; A. Agniel ; J. F. Demonet ; B. Doyon ; M. Puel ; J. P. Marc-Vergnes ; A. Rascol | Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease: lack of correlation with clinical or neuropsychological improvements |
| 001B85 |
T. Venisse ; J. L. Montastruc ; A. Rascol | Pharmacologie clinique et traitement de la maladie de Parkinson |
| 001B91 |
H. Allain ; A. Gosselin ; D. Milon ; O. Sabouraud | Dysphagie au cours de la maladie de Parkinson |
